NMS Capital has exited its investment in Flourish Research, a US-based clinical trial organization, through a sale to Genstar Capital. No financial terms were disclosed.

Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Affimed (AFMD – Research Report), retaining the price target ...

Utilizing the Dural Substitute Confetti technique during spinal cord stimulation trial implantation may reduce complications and shorten surgery time.

LifeSci Capital analyst Anshul Dhankher maintained a Buy rating on Perspective Therapeutics (CATX – Research Report ... The company has shown consistent execution in its clinical programs, ...

Original research ranges from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative ...

Objectives Secondary prevention of rheumatoid arthritis (RA) is generally considered potentially impactful because the entire ...

Additional member institutions will be announced and onboarded in subsequent phases. “The velocity of AI innovations ... we translate discovery into application and interconnect clinical care, ...

For instance, AI algorithms can rapidly screen millions of compounds, significantly speeding up the initial phases of drug ..